Pfizer (PFE) Tax Provisions (2009 - 2026)
Pfizer (PFE) posted quarterly Tax Provisions of $461.0 million for Q1 2026, up 343.92% year-over-year from $103.8 million in Q1 2025, and up 23150.0% quarter-over-quarter from -$2.0 million in Q4 2025.
Pfizer (PFE) Tax Provisions (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Tax Provisions for 18 consecutive years, with $461.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Tax Provisions rose 343.92% year-over-year to $461.0 million; the TTM figure through Mar 2026 stood at $384.0 million (up 5.79% YoY), while the FY2025 annual figure was -$266.0 million, down 850.0% from the prior year.
- Tax Provisions rose to $461.0 million in Q1 2026 per PFE's latest filing, from -$2.0 million in the prior quarter.
- Across five years, Tax Provisions topped out at $1.6 billion in Q3 2022 and bottomed at -$780.0 million in Q4 2023.
- Historically, Tax Provisions has averaged $257.9 million across 5 years, with a median of $141.0 million in 2025.
- Annual changes were most pronounced in 2025 — Tax Provisions plunged 164.51% — and 2026, when it jumped 343.92%.
- Pfizer's Tax Provisions stood at $1.6 billion in 2022, then tumbled by 149.68% to -$780.0 million in 2023, then soared by 150.38% to $393.0 million in 2024, then slumped by 100.51% to -$2.0 million in 2025, then jumped by 23150.0% to $461.0 million in 2026.
- Business Quant data shows PFE's Tax Provisions at $461.0 million in Q1 2026, -$2.0 million in Q4 2025, and -$216.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 1.21 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 662.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 654.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 1.01 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 291.00 Mn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 393.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 242.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -407.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 266.99 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -524.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | -407.00 Mn |
| Mar 29, 2026 | 461.00 Mn |
| Dec 31, 2025 | -2.00 Mn |
| Sep 28, 2025 | -216.00 Mn |
| Jun 29, 2025 | 141.00 Mn |
| Mar 30, 2025 | -189.00 Mn |
| Sep 29, 2024 | 393.00 Mn |
| Jun 30, 2024 | -134.00 Mn |
| Mar 31, 2024 | 293.00 Mn |
| Dec 31, 2023 | -780.00 Mn |
| Jul 2, 2023 | -71.00 Mn |
| Apr 2, 2023 | 715.00 Mn |
| Jul 3, 2022 | 1.57 Bn |
| Apr 3, 2022 | 1.17 Bn |
| Oct 3, 2021 | 1.60 Bn |
| Jul 4, 2021 | 1.12 Bn |
| Apr 4, 2021 | 808.00 Mn |
| Sep 27, 2020 | 434.00 Mn |
| Jun 28, 2020 | 422.00 Mn |
| Mar 29, 2020 | 359.00 Mn |